Publicação
Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis
| Resumo: | Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p<0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p<0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept. Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. |
|---|---|
| Autores principais: | Pessoa, Bernardete |
| Outros Autores: | Malheiro, Luísa; Carneiro, Inês; Monteiro, Sílvia; Coelho, João; Coelho, Constança; Figueira, João; Meireles, Angelina; Melo Beirão, João Nuno |
| Assunto: | Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| Ano: | 2021 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório da Universidade de Lisboa |
| _version_ | 1865920790075015168 |
|---|---|
| author | Pessoa, Bernardete |
| author2 | Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Figueira, João Meireles, Angelina Melo Beirão, João Nuno |
| author2_role | author author author author author author author author |
| author_facet | Pessoa, Bernardete Pessoa, Bernardete Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Figueira, João Meireles, Angelina Melo Beirão, João Nuno Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Figueira, João Meireles, Angelina Melo Beirão, João Nuno |
| author_role | author |
| contributor_name_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| country_str | PT |
| creators_json_str | [{\"Person.name\":\"Pessoa, Bernardete\"},{\"Person.name\":\"Malheiro, Luísa\"},{\"Person.name\":\"Carneiro, Inês\"},{\"Person.name\":\"Monteiro, Sílvia\"},{\"Person.name\":\"Coelho, João\"},{\"Person.name\":\"Coelho, Constança\",\"Person.identifier.orcid\":\"0000-0002-5331-2257\"},{\"Person.name\":\"Figueira, João\"},{\"Person.name\":\"Meireles, Angelina\"},{\"Person.name\":\"Melo Beirão, João Nuno\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| datacite.creators.creator.creatorName.fl_str_mv | Pessoa, Bernardete Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Figueira, João Meireles, Angelina Melo Beirão, João Nuno |
| datacite.date.Accepted.fl_str_mv | 2021-01-01T00:00:00Z |
| datacite.date.available.fl_str_mv | 2022-08-03T16:29:30Z |
| datacite.date.embargoed.fl_str_mv | 2022-08-03T16:29:30Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| datacite.titles.title.fl_str_mv | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| dc.contributor.none.fl_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| dc.creator.none.fl_str_mv | Pessoa, Bernardete Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Figueira, João Meireles, Angelina Melo Beirão, João Nuno |
| dc.date.Accepted.fl_str_mv | 2021-01-01T00:00:00Z |
| dc.date.available.fl_str_mv | 2022-08-03T16:29:30Z |
| dc.date.embargoed.fl_str_mv | 2022-08-03T16:29:30Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10451/54052 |
| dc.language.none.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Dove Press |
| dc.rights.cclincense.fl_str_mv | http://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.subject.none.fl_str_mv | Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| dc.title.fl_str_mv | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 |
| description | Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p<0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p<0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept. Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | article |
| fulltext.url.fl_str_mv | https://repositorio.ulisboa.pt/bitstreams/4077e8b8-6fac-4189-b182-5ef06c979539/download |
| id | ul_45e1ca6bd2fd2a7e78c63dd6d20f4b2c |
| identifier.url.fl_str_mv | http://hdl.handle.net/10451/54052 |
| instacron_str | ul |
| institution | Universidade de Lisboa |
| instname_str | Universidade de Lisboa |
| language | eng |
| network_acronym_str | ul |
| network_name_str | Repositório da Universidade de Lisboa |
| oai_identifier_str | oai:repositorio.ulisboa.pt:10451/54052 |
| organization_str_mv | urn:organizationAcronym:ul |
| person_str_mv | Pessoa, Bernardete Malheiro, Luísa Carneiro, Inês Monteiro, Sílvia Coelho, João Coelho, Constança Coelho, Constança https://www.ciencia-id.pt/7515-8385-064B 7515-8385-064B http://orcid.org/0000-0002-5331-2257 0000-0002-5331-2257 Figueira, João Meireles, Angelina Melo Beirão, João Nuno |
| publishDate | 2021 |
| publisher.none.fl_str_mv | Dove Press |
| reponame_str | Repositório da Universidade de Lisboa |
| repository_id_str | urn:repositoryAcronym:ul |
| service_str_mv | urn:repositoryAcronym:ul |
| spelling | engDove Presspt_PTAim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p<0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p<0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept. Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement.application/pdfpt_PTIntravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysisPessoa, BernardeteMalheiro, LuísaCarneiro, InêsMonteiro, SílviaCoelho, JoãoPersonalCoelho, ConstançaDSpacehttp://dspace.org/items/6b90db77-8f9c-48a9-a91e-6410d4b862e6DSpacehttp://dspace.org/items/6b90db77-8f9c-48a9-a91e-6410d4b862e6CoelhoConstançaCiência IDhttps://www.ciencia-id.pt7515-8385-064BORCIDhttp://orcid.org0000-0002-5331-2257Scopus Author IDhttps://www.scopus.com7005608345Figueira, JoãoMeireles, AngelinaMelo Beirão, João NunoHostingInstitutionOrganizationalRepositório Científico de Acesso Aberto da ULisboae-mailmailto:repositorio@reitoria.ulisboa.ptrepositorio@reitoria.ulisboa.ptISSNIsPartOf1177-5467DOIIsPartOf10.2147/OPTH.S2806442022-08-03T16:29:30Z20212021-01-01T00:00:00ZHandlehttp://hdl.handle.net/10451/54052http://purl.org/coar/access_right/c_abf2open accessAfliberceptBevacizumabDiabetic macular edemaRanibizumabRefractory1849265 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal article2021http://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorio.ulisboa.pt/bitstreams/4077e8b8-6fac-4189-b182-5ef06c979539/downloadClinical OphthalmologyVolume 15253260 |
| spellingShingle | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis Pessoa, Bernardete Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory Pessoa, Bernardete Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| status | SINGLETON |
| subject.fl_str_mv | Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| title | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| title_full | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| title_fullStr | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| title_full_unstemmed | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| title_short | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| title_sort | Intravitreal Ranibizumab or Aflibercept after Bevacizumab in diabetic macular edema: exploratory retrospective analysis |
| topic | Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| topic_facet | Aflibercept Bevacizumab Diabetic macular edema Ranibizumab Refractory |
| url | http://hdl.handle.net/10451/54052 |
| visible | 1 |